PHVS 收益：关于 Pharvaris NV 的人工智能洞察

主页

股票

PHVS

PHVS 收益

Pharvaris NV

$27.01

1.5%

$0.4

收盘价：Feb 18, 16:00:00 GMT-5

$27.01

盘后：Feb 18, 20:00:00 GMT-5

概述预测收益股息财务数据

最新收益结果： Q3 '25

报告： 2025-11-12

每股收益（EPS）估算值

报告的每股收益

惊喜

$-0.68

$-0.59

-13.23%

预计收入

报告的收益

惊喜

历史收益

季度性

年度

EPS

收入

财报周期	预估	已公布	预期差	结果
Q3 '25	$-0.68	$-0.59	-13.23%	MISSED
Q2 '25	$-0.78	$-0.83	+6.41%	BEAT
Q1 '25	$-0.77	$-0.85	+10.38%	BEAT
Q4 '24	$-0.73	$-0.64	-12.32%	MISSED
Q3 '24	$-0.62	$-0.77	+24.19%	BEAT

关键数据

前收盘价

$26.61

开盘价

$26.55

当日区间

$26.39 - $27.17

52周范围

$11.51 - $29.79

交易量

52.3K

平均成交量

312.6K

每股收益（TTM）

-2.92

股息收益率

市值

$1.7B

什么是 PHVS？

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

功能特性

资源